United Kingdom-based consumer packaged goods giant Reckitt Benckiser Group Plc (RB) acquired the India-based OTC major company, Paras Pharmaceuticals Limited (Paras), on December 13, 2010, for US$ 726 million (£ 454 million). Until a few years earlier, RB had had a relatively low contribution of revenue from the Health & Personal Care (H&PC) category. However, the acquisition of Boots Healthcare International (in 2005) and SSL International Plc (in 2010) had significantly increased its revenue from this category. The acquisition of Paras was expected to further boost its presence in the H&PC category and to strengthen RB’s position in the world’s second fastest growing economy.
» To understand various issues and challenges in Mergers and Acquisitions (M&A).
» To understand the synergies and challenges associated with this buyout.
» To understand the rationale behind the acquisition and discuss and debate the pros and cons of RB’s decision to acquire Paras.
» To analyze whether RB’s decision to acquire Paras at 8.2 times of revenue is justified.
» To explore strategies that RB could adopt to effectively integrate Paras into its businesses and realize the potential synergies.
Mergers and Acquisitions, Acquisition, Buyout, Synergies, Globalization, Investor Relations, Emerging markets, Developing markets, India, Middle Eastern-North Africa (MENA) markets, Fast Moving Consumer Goods, Over-the-counter segment, Pharmaceuticals, Reckitt Benckiser, Paras
Uk-Based FMCG Major Buys Paras
- Next Page>>